T1	Age 2 13	54-year-old
T2	Gender 14 20	female
T3	Activity 25 33	admitted
E1	Activity:T3 
T4	Other_entity 41 49	hospital
T5	Disease_disorder 85 87	HF
E2	Disease_disorder:T5 
T6	Time 115 134	three years earlier
E3	Time:T6 
T7	Disease_disorder 140 148	acute MI
E4	Disease_disorder:T7 
T8	Diagnostic_procedure 162 182	coronary angiography
E5	Diagnostic_procedure:T8 
T9	Sign_symptom 184 228	total occlusion of the right coronary artery
E6	Sign_symptom:T9 
T10	Anatomical_structure 207 228	right coronary artery
T11	Sign_symptom 234 297	collateral circulation from the left descending coronary artery
E7	Sign_symptom:T11 
T12	Anatomical_structure 266 297	left descending coronary artery
R1	MODIFIER Arg1:E3 Arg2:E4	
*	OVERLAP E5 E4 E6 E7
T13	Therapeutic_procedure 334 355	coronary intervention
E8	Therapeutic_procedure:T13 
A1	POLARITY E8 NEG
T14	Activity 364 379	hospitalisation
E9	Activity:T14 
T15	Disease_disorder 386 388	MI
E10	Disease_disorder:T15 
T16	Duration 357 379	During hospitalisation
E11	Duration:T16 
R2	MODIFIER Arg1:E11 Arg2:E10	
T18	Other_event 420 430	classified
E13	Other_event:T18 
T19	Other_entity 408 415	patient
T20	Diagnostic_procedure 519 530	examination
E14	Diagnostic_procedure:T20 
T22	Lab 561 600	Nterminal-pro-brain natriuretic peptide
E15	Lab:T22 
T21	Qualitative_concept 543 557	elevated level
R3	MODIFIER Arg1:T21 Arg2:E15	
T23	Lab 602 611	NT-proBNP
E16	Lab:T23 
T24	Quantitative_concept 613 624	10581 pg/mL
R4	MODIFIER Arg1:T24 Arg2:E16	
T25	Sign_symptom 627 646	cardiac enlargement
E17	Sign_symptom:T25 
T26	Lab 665 704	left ventricular end-diastolic diameter
E18	Lab:T26 
T27	Qualitative_concept 655 664	increased
R5	MODIFIER Arg1:T27 Arg2:E18	
T28	Lab 706 711	LVEDD
E19	Lab:T28 
T29	Quantitative_concept 713 718	81 mm
R6	MODIFIER Arg1:T29 Arg2:E19	
T30	Lab 725 759	left ventricular ejection fraction
E20	Lab:T30 
T31	Lab 761 765	LVEF
E21	Lab:T31 
T32	Quantitative_concept 767 770	25%
R7	MODIFIER Arg1:T32 Arg2:E21	
T33	Qualitative_concept 721 724	low
R8	MODIFIER Arg1:T33 Arg2:E20	
T34	Sign_symptom 777 839	akinesis of the inferior, inferoseptal and inferolateral walls
E22	Sign_symptom:T34 
T35	Anatomical_structure 793 839	inferior, inferoseptal and inferolateral walls
T36	Sign_symptom 852 907	global hypokinesis of other walls of the left ventricle
E23	Sign_symptom:T36 
T37	Sign_symptom 655 704	increased left ventricular end-diastolic diameter
E24	Sign_symptom:T37 
T38	Sign_symptom 543 600	elevated level of Nterminal-pro-brain natriuretic peptide
E25	Sign_symptom:T38 
*	OVERLAP E14 E25 E26 E24 E22 E23
T39	Sign_symptom 721 759	low left ventricular ejection fraction
E26	Sign_symptom:T39 
*	OVERLAP E18 E19
*	OVERLAP E21 E20
*	OVERLAP E16 E15
T40	Anatomical_structure 874 907	other walls of the left ventricle
T41	Time 909 919	Since then
E27	Time:T41 
R9	AFTER Arg1:E27 Arg2:E14	
T42	Other_entity 925 932	patient
T43	Therapeutic_procedure 942 949	treated
E28	Therapeutic_procedure:T43 
T44	Disease_disorder 954 957	CAD
E29	Disease_disorder:T44 
*	OVERLAP E28 E29 E33 E34 E35 E37 E36 E38 E39 E30 E31 E32
T45	Disease_disorder 974 995	arterial hypertension
E30	Disease_disorder:T45 
T46	Disease_disorder 997 1018	hypercholesterolaemia
E31	Disease_disorder:T46 
T47	Disease_disorder 1020 1042	ventricular arrhythmia
E32	Disease_disorder:T47 
T48	Medication 1044 1054	carvedilol
E33	Medication:T48 
T49	Medication 1056 1064	ramipril
E34	Medication:T49 
T50	Medication 1066 1080	spironolactone
E35	Medication:T50 
T51	Medication 1094 1106	atorvastatin
E36	Medication:T51 
T52	Medication 1082 1092	furosemide
E37	Medication:T52 
T53	Medication 1108 1121	trimetazidine
E38	Medication:T53 
T54	Medication 1123 1130	aspirin
E39	Medication:T54 
T55	Time 1133 1149	Two months later
E40	Time:T55 
R10	AFTER Arg1:E40 Arg2:E27	
T56	Activity 1162 1171	admission
E41	Activity:T56 
T57	Other_entity 1179 1187	hospital
T58	Duration 1151 1157	during
E42	Duration:T58 
R11	MODIFIER Arg1:E42 Arg2:E41	
T59	Qualitative_concept 1208 1216	improved
T60	Lab 1189 1203	all parameters
E43	Lab:T60 
R12	MODIFIER Arg1:T59 Arg2:E43	
T62	Lab 1233 1242	NT-proBNP
E45	Lab:T62 
T61	Lab 1218 1222	NYHA
E44	Lab:T61 
T63	Qualitative_concept 1223 1231	class II
R13	MODIFIER Arg1:T63 Arg2:E44	
T64	Quantitative_concept 1243 1253	1869 pg/mL
R14	MODIFIER Arg1:T64 Arg2:E45	
T65	Lab 1255 1260	LVEDD
E46	Lab:T65 
T66	Quantitative_concept 1261 1266	73 mm
R15	MODIFIER Arg1:T66 Arg2:E46	
T67	Lab 1268 1272	LVEF
E47	Lab:T67 
T68	Quantitative_concept 1273 1276	35%
R16	MODIFIER Arg1:T68 Arg2:E47	
T69	Sign_symptom 1282 1322	inferior and inferolateral wall akinesis
E48	Sign_symptom:T69 
T70	Sign_symptom 1336 1362	hypokinesis of other walls
E49	Sign_symptom:T70 
T71	Qualitative_concept 1327 1335	moderate
R17	MODIFIER Arg1:T71 Arg2:E49	
T72	Anatomical_structure 1282 1313	inferior and inferolateral wall
T73	Anatomical_structure 1351 1362	other walls
*	OVERLAP E44 E43 E45 E46 E47 E48 E49 E41 E40
T74	Diagnostic_procedure 1365 1398	Cardiovascular magnetic resonance
E50	Diagnostic_procedure:T74 
T75	Diagnostic_procedure 1400 1403	CMR
E51	Diagnostic_procedure:T75 
*	OVERLAP E51 E50
T76	Other_entity 1422 1432	department
T77	Diagnostic_procedure 1440 1467	late gadolinium enhancement
E52	Diagnostic_procedure:T77 
#1	AnnotatorNotes E52	This is a chemical used as a contrast agent
T78	Anatomical_structure 1481 1493	inferoseptal
T79	Anatomical_structure 1495 1503	mid-wall
T80	Anatomical_structure 1506 1514	inferior
T81	Anatomical_structure 1516 1531	sub-endocardial
T82	Anatomical_structure 1537 1550	inferolateral
T83	Anatomical_structure 1552 1562	transmural
T84	Anatomical_structure 1564 1569	walls
T85	Anatomical_structure 1481 1569	inferoseptal (mid-wall), inferior (sub-endocardial) and inferolateral (transmural) walls
T86	Sign_symptom 1603 1612	infection
E53	Sign_symptom:T86 
T87	Sign_symptom 1616 1621	fever
E54	Sign_symptom:T87 
T88	Time 1596 1602	recent
E55	Time:T88 
A2	POLARITY E53 NEG
A3	POLARITY E54 NEG
R18	MODIFIER Arg1:E55 Arg2:E53	
R19	MODIFIER Arg1:E55 Arg2:E54	
T89	Anatomical_structure 1639 1641	LV
T90	Sign_symptom 1639 1652	LV dilatation
E56	Sign_symptom:T90 
T91	Diagnostic_procedure 1682 1685	LGE
E57	Diagnostic_procedure:T91 
T92	Disease_disorder 1690 1701	myocarditis
E58	Disease_disorder:T92 
T93	Anatomical_structure 1709 1740	inferoseptal and inferior walls
T94	Disease_disorder 1690 1740	myocarditis in the inferoseptal and inferior walls
E59	Disease_disorder:T94 
T95	Duration 1753 1764	persistence
E60	Duration:T95 
T96	Lab 1805 1815	troponin I
E61	Lab:T96 
T97	Quantitative_concept 1817 1828	0.014 ng/mL
R20	MODIFIER Arg1:T97 Arg2:E61	
T98	Qualitative_concept 1770 1787	slightly elevated
R21	MODIFIER Arg1:T98 Arg2:E61	
T99	Diagnostic_procedure 1831 1847	Echocardiography
E62	Diagnostic_procedure:T99 
T100	Qualitative_concept 1859 1862	low
T101	Anatomical_structure 1887 1902	coronary artery
T102	Sign_symptom 1887 1910	coronary artery changes
E63	Sign_symptom:T102 
T103	Sign_symptom 1915 1936	cardiac contractility
E64	Sign_symptom:T103 
T104	Other_event 1863 1874	correlation
E65	Other_event:T104 
A4	POLARITY E65 POS
R22	MODIFIER Arg1:T100 Arg2:E65	
*	OVERLAP E63 E65 E64 E62
T105	Disease_disorder 1997 2008	myocarditis
E66	Disease_disorder:T105 
A5	POLARITY E66 UNCERTAIN
T106	Qualitative_concept 1984 1993	suspicion
R23	MODIFIER Arg1:T106 Arg2:E66	
T107	Diagnostic_procedure 2047 2068	endomyocardial biopsy
E67	Diagnostic_procedure:T107 
T108	Diagnostic_procedure 2070 2073	EMB
E68	Diagnostic_procedure:T108 
*	OVERLAP E68 E67 E66
T109	Therapeutic_procedure 2089 2092	EMB
E69	Therapeutic_procedure:T109 
T110	Sign_symptom 2163 2175	myocytolysis
E70	Sign_symptom:T110 
T111	Sign_symptom 2180 2199	myocardial fibrosis
E71	Sign_symptom:T111 
T112	Lab 2243 2246	CD3
E72	Lab:T112 
T113	Lab 2248 2251	CD4
E73	Lab:T113 
T114	Lab 2253 2271	CD8-positive cells
E74	Lab:T114 
T115	Lab 2273 2283	single LCA
E75	Lab:T115 
T116	Lab 2285 2304	CD68-positive cells
E76	Lab:T116 
T117	Diagnostic_procedure 2308 2327	Electron microscopy
E77	Diagnostic_procedure:T117 
T118	Diagnostic_procedure 2331 2334	EMB
E78	Diagnostic_procedure:T118 
T119	Lab 2331 2342	EMB samples
E79	Lab:T119 
*	OVERLAP E77 E79
T120	Sign_symptom 2352 2411	ultrastructural changes in all elements of the heart tissue
E80	Sign_symptom:T120 
T121	Anatomical_structure 2399 2404	heart
T122	Anatomical_structure 2413 2423	myofibrils
T123	Anatomical_structure 2425 2432	nucleus
T124	Anatomical_structure 2434 2447	mitochondrion
T125	Anatomical_structure 2449 2470	endoplasmic reticulum
T126	Anatomical_structure 2472 2496	intercellular connection
#2	AnnotatorNotes T126	Not an anatomical structure, but rather a biological feature
T127	Anatomical_structure 2498 2511	blood vessels
T128	Sign_symptom 2521 2526	virus
E81	Sign_symptom:T128 
A6	POLARITY E81 NEG
T129	Disease_disorder 2542 2544	HF
E82	Disease_disorder:T129 
T130	Disease_disorder 2549 2552	CAD
E83	Disease_disorder:T130 
T131	Therapeutic_procedure 2553 2562	treatment
E84	Therapeutic_procedure:T131 
T132	Time 2656 2674	three months later
E85	Time:T132 
T133	Activity 2691 2705	rehospitalised
E86	Activity:T133 
T134	Disease_disorder 2717 2719	HF
E87	Disease_disorder:T134 
T135	Qualitative_concept 2720 2732	exacerbation
R24	MODIFIER Arg1:T135 Arg2:E87	
T17	Quantitative_concept 434 509	Class III according to the New York Heart Association (NYHA) classification
R25	MODIFIER Arg1:T17 Arg2:E10	
T136	Lab 2734 2738	NYHA
E12	Lab:T136 
T137	Lab 2750 2759	NT-proBNP
E88	Lab:T137 
T138	Lab 2772 2780	troponin
E89	Lab:T138 
T139	Lab 2790 2795	LVEDD
E90	Lab:T139 
T140	Lab 2803 2807	LVEF
E91	Lab:T140 
T141	Quantitative_concept 2739 2748	Class III
T142	Quantitative_concept 2760 2770	1980 pg/dL
T143	Quantitative_concept 2781 2788	3 ng/mL
T144	Quantitative_concept 2796 2801	77 mm
T145	Quantitative_concept 2808 2811	30%
R26	MODIFIER Arg1:T141 Arg2:E12	
R27	MODIFIER Arg1:T142 Arg2:E88	
R28	MODIFIER Arg1:T143 Arg2:E89	
R29	MODIFIER Arg1:T144 Arg2:E90	
R30	MODIFIER Arg1:T145 Arg2:E91	
T146	Lab 2818 2865	ventricular extrasystoles without complex forms
E92	Lab:T146 
T147	Quantitative_concept 2813 2817	8048
R31	MODIFIER Arg1:T147 Arg2:E92	
T148	Diagnostic_procedure 2869 2898	24-hour Holter ECG monitoring
E93	Diagnostic_procedure:T148 
*	OVERLAP E93 E92
T149	Duration 2869 2876	24-hour
E94	Duration:T149 
T150	Diagnostic_procedure 2916 2936	coronary angiography
E95	Diagnostic_procedure:T150 
T151	Diagnostic_procedure 3062 3109	real-time polymerase chain reaction examination
E96	Diagnostic_procedure:T151 
T152	Diagnostic_procedure 3111 3115	qPCR
E97	Diagnostic_procedure:T152 
T153	Activity 3121 3130	performed
E98	Activity:T153 
T154	Diagnostic_procedure 3206 3209	EMB
E99	Diagnostic_procedure:T154 
T155	Diagnostic_procedure 3248 3252	qPCR
E100	Diagnostic_procedure:T155 
T156	Disease_disorder 3291 3311	viral cardiomyopathy
E101	Disease_disorder:T156 
T157	Lab 3278 3285	HEV RNA
E102	Lab:T157 
T158	Therapeutic_procedure 3357 3384	treatment with interferon-β
E103	Therapeutic_procedure:T158 
T159	Quantitative_concept 3435 3442	62.5 μg
T160	Quantitative_concept 3444 3451	0.25 mL
T161	Time 3460 3470	first week
E104	Time:T161 
T162	Quantitative_concept 3472 3478	125 μg
T163	Quantitative_concept 3480 3486	0.5 mL
T164	Time 3495 3517	second and third weeks
E105	Time:T164 
T165	Quantitative_concept 3523 3531	187.5 μg
T166	Quantitative_concept 3533 3540	0.75 mL
T167	Time 3557 3614	every other day from the fourth to the twenty-fourth week
E106	Time:T167 
T168	Time 3625 3637	fourth month
E107	Time:T168 
T169	Diagnostic_procedure 3656 3659	EMB
E108	Diagnostic_procedure:T169 
T170	Lab 3681 3688	HEV RNA
E109	Lab:T170 
A7	POLARITY E109 NEG
T171	Anatomical_structure 3709 3714	heart
T172	Anatomical_structure 3709 3729	heart tissue samples
T173	Time 3737 3747	six months
E110	Time:T173 
T174	Therapeutic_procedure 3751 3778	treatment with interferon-β
E111	Therapeutic_procedure:T174 
T175	Other_entity 3784 3791	patient
T176	Qualitative_concept 3805 3818	significantly
T177	Qualitative_concept 3796 3804	improved
T178	Lab 3820 3824	NYHA
E112	Lab:T178 
T179	Quantitative_concept 3825 3832	class I
R32	MODIFIER Arg1:T179 Arg2:E112	
T180	Lab 3834 3843	NT-proBNP
E113	Lab:T180 
T181	Quantitative_concept 3844 3853	512 pg/mL
R33	MODIFIER Arg1:T181 Arg2:E113	
T182	Lab 3855 3860	LVEDD
E114	Lab:T182 
T183	Quantitative_concept 3861 3866	68 mm
R34	MODIFIER Arg1:T183 Arg2:E114	
T184	Lab 3868 3872	LVEF
E115	Lab:T184 
T185	Quantitative_concept 3873 3876	45%
R35	MODIFIER Arg1:T185 Arg2:E115	
T186	Qualitative_concept 3880 3888	decrease
T187	Diagnostic_procedure 3913 3937	24-hour Holter recording
E116	Diagnostic_procedure:T187 
T188	Lab 3906 3909	ExV
E117	Lab:T188 
*	OVERLAP E116 E117
T189	Quantitative_concept 3957 3961	1889
T190	Lab 3962 3988	ExV, without complex forms
E118	Lab:T190 
R36	MODIFIER Arg1:T189 Arg2:E118	
T191	Sign_symptom 4002 4016	drug reactions
E119	Sign_symptom:T191 
T192	Qualitative_concept 3994 4001	adverse
R37	MODIFIER Arg1:T192 Arg2:E119	
A8	POLARITY E119 NEG
T193	Time 4031 4039	two-year
E120	Time:T193 
T194	Activity 4040 4049	follow-up
E121	Activity:T194 
R38	MODIFIER Arg1:E120 Arg2:E121	
T195	Lab 3168 3175	samples
E122	Lab:T195 
T196	Lab 3141 3160	viral nucleic acids
E123	Lab:T196 
T197	Time 3186 3209	during the previous EMB
E124	Time:T197 
T198	Lab 3226 3242	frozen specimens
E125	Lab:T198 
T199	Activity 3316 3325	diagnosed
E126	Activity:T199 
R39	MODIFIER Arg1:T160 Arg2:T159	
R40	MODIFIER Arg1:E104 Arg2:T159	
R41	MODIFIER Arg1:T163 Arg2:T162	
R42	MODIFIER Arg1:E105 Arg2:T162	
R43	MODIFIER Arg1:T166 Arg2:T165	
R44	MODIFIER Arg1:E106 Arg2:T165	
